Lung deposition of formoterol HFA in healthy volunteers, asthmatic and COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 314s Year: 2005
Inhibitory effects of budesonide and formoterol in combination on TGFβ-induced proteoglycan production by bronchial biopsy fibroblasts from healthy and mild asthmatic subjects Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Effects on adrenal function of a new combination of fluticasone propionate/formoterol fumarate administered to asthmatic patients and healthy subjects Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Effect of salmeterol in asthmatic patients with low sputum eosinophils Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001
Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 710s Year: 2004
Comparison of the effectiveness of azithromycin and budesonide versus theophylline and budesonide in the suppression of pro-inflammatory cytokines in patients with COPD Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001
The pharmacokinetics of inhaled NVA237 in COPD patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparison of the effects of zafirlucast and montelucast therapy on the airway hiperreactivity in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 430s Year: 2001
Comparison of pulmonary and systemic absoption of two HFA formulations of salmeterol in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
The effect of formoterol in elderly COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005
Bronchodilation from formoterol and terbutaline has similar onset of action in asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Absence of sputum eosinophils in subjects with symptomatic asthma on inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 274s Year: 2002
Lack of glucocorticoid receptor activation by formoterol and salmeterol in human bronchial epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 454s Year: 2003
Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002